KOSPI 8,400 mark reclaimed, pharmaceutical, biotech and healthcare stocks rally
KOSPI 8,400 mark, with pharmaceutical, biotech and healthcare sectors rising in tandem. Chong Kun Dang reported resilient earnings thanks to the effect of Wegovy, while HanAll Biopharma’s drug development achievements were accompanied by a proposed target price of 13 ten thousand won.
KOSPI 8,400 mark. The index closed up in the 2% range. Gains were led by pharmaceutical, biotech and healthcare-related stocks.
Chong Kun Dang announced resilient earnings thanks to the effect of Wegovy. The company said new drugs are driving a revaluation of its share price. The disclosure was issued in 5 month 29.
HanAll Biopharma announced that it had achieved a world-first result. An analysis proposing a target price of 13 ten thousand won was mentioned in connection with this. The related information was reported on 5 month 29.
InBody announced that it will link an AI-based body composition management service with Naver Healthcare. The two companies said they are collaborating to connect users’ body composition data to the platform. The company said the collaboration will enhance personalized health management features.
Meju disclosed that it had received manufacturing approval for a next-generation product. The company said news of the approval had raised expectations for improved performance. The stock surged immediately after the approval was announced.
Daewoong, Seers, and TR announced that they will jointly develop a next-generation smart ward solution. The three companies said they will pursue development aimed at automating ward operations and integrating patient monitoring. The contract terms and schedule were not disclosed.
Related disclosures were released in succession over 5month 28day and 5month 29day. These developments led to a broad rise in the pharmaceuticals, biotechnology, and healthcare sectors. Investors should check each company’s original disclosure.